Form D · Biotechnology
BioRestorative Therapies, Inc.
Melville, NY · CIK 0001505497
Offering snapshot reported Oct 9, 2025 · SEC filing
- Reported sold
- $1.4M Offering amount: $1.4M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2025 | Initial | $1,398,628 | No comparison | 16 | SEC filing |
| May 9, 2016 | Amendment | $14,395,044 | $10,095,044vs Jan 13, 2015 | 81 | SEC filing |
| Nov 25, 2015 | Amendment | $12,549,450 | $8,249,450vs Jan 13, 2015 | 67 | SEC filing |
| Jan 13, 2015 | Amendment | $4,300,000 | $3,514,386vs Mar 20, 2014 | 52 | SEC filing |
| Mar 26, 2014 | Amendment | $585,809 | $573,809vs Dec 17, 2013 | 21 | SEC filing |
| Mar 20, 2014 | Initial | $785,614 | No comparison | 10 | SEC filing |
| Dec 17, 2013 | Initial | $12,000 | No comparison | 2 | SEC filing |
| Apr 18, 2012 | Initial | $1,975,000 | No comparison | 6 | SEC filing |
| Mar 9, 2011 | Amendment | $1,472,500 | $1,337,500vs Nov 16, 2010 | 15 | SEC filing |
| Nov 16, 2010 | Initial | $135,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-560305
The amounts shown above exclude the sales commissions payable in connection with the concurrent public offering relating to the offer and sale of shares of the Company's common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cova Capital Partners LLC | 109761 |
Source: Form D, filed Oct 9, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lance Alstodt | Director, Executive |
| Tommy Berger | Promoter |
| Robert B. Catell | Director |
| Mandy Clark | Executive |
| Mandy Clyde | Executive |
| John M. Desmarais | Director |
| Edward L. Field | Executive |
| Robert Kristal | Executive |
| Nickolay V Kukekov | Director |
| Gloria Mc Connell | Promoter |
| Richard Proodian | Director, Executive |
| A. Jeffrey Radov | Director |
| David A Rosa | Director |
| Joseph Ross | Director, Executive |
| Charles S. Ryan | Director |
| Joel San Antonio | Director |
| Francisco Silva | Director, Executive |
| Joseph B. Swiader | Director |
| Paul Jude Tonna | Director |
| Kurt Wagner | Director, Executive |
| Mark Weinreb | Director, Executive |
| Patrick F Williams | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
40 Marcus Drive Suite One
Melville, NY, 11747
Melville, NY, 11747